Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215253 · ClinicalTrials.gov registry record · Phase 3
Ranolazine Implantable Cardioverter-Defibrillator Trial
A Phase 3 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,012
- Enrollment target
NCT01215253: Completed Phase 3 study, sponsored by University of Rochester.
NCT01215253 is a Phase 3 study that has completed, run by University of Rochester. The registered enrollment target is 1,012 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01215253, a Phase 3 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,012 participants
- Enrollment target
Study Summary
The purpose of the study is to see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs). This drug will be used with standard medications that is routinely prescribed in enrolled patients.
Primary Outcome
Primary endpoint of the study will be defined as a composite endpoint consisting of Ventricular Tachycardia or Ventricular Fibrillation requiring antitachycardia pacing (ATP) therapy, implantable cardioverter-defibrillator (ICD) shock, or death, whichever occurs first.
Interventions
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,012 participants |
| Start Date | 2011-09 |
| Est. Completion | 2017-02-28 |
| Phase | Phase 3 |
What the finished NCT01215253 record still lists
NCT01215253 is an interventional study that assigns participants to a tested intervention. Its 1,012 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 1 intervention - of which Ranolazine is the first listed.
NCT01215253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01215253 about?
NCT01215253 is a clinical study titled "Ranolazine Implantable Cardioverter-Defibrillator Trial". The purpose of the study is to see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs). This drug will be used with standard medications that is routinely prescribed in enrolled patients.
What is the current status of trial NCT01215253?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,012 participants. The study started on 2011-09. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT01215253?
The interventions under investigation include: Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01215253?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01215253's enrollment target sits among peer trials
1,012 294th of 2000 higher than 1,706 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia